SIGNAL GRIDv0.1

AstraZeneca investors baulk at $400 billion Bristol Myers talks - Reuters

1 sources2 storiesFirst seen 8/3/2026Score48Mixed Progress
Single Source
CoverageRecencyEngagementVelocityBignessConfidenceClipability
Bigness
48
Coverage
13
Recency
95
Engagement
20
Velocity
100
Confidence
49
Clipability
60
Polarization
0
Claims
4
Contradictions
0
Breakthrough
50

Sentiment Mix

Positive0%
Neutral100%
Negative0%

Geography

Europe

Expert Signals

Politics - Google News US Headlines

source2 mentions

AI-Generated Claims

Generated from linked receipts; click sources for full context.

Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival - Barron's.

Supported by 1 story

Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival Barron'sAstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed' cnbc.comStruggling to make sense of AstraZeneca-BMS Financial TimesEditor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea Fierce PharmaAstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

Supported by 1 story

AstraZeneca investors baulk at $400 billion Bristol Myers talks

Supported by 1 story

MarketWatchAstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb Yahoo FinanceEditor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea Fierce Pharma

Supported by 1 story

Related Events

Timeline (2 stories)

Receipts (2)

Bias Snapshot

Center
Left 0%Center 100%Right 0%
Blognews.google.com8/3/2026
Blognews.google.com8/3/2026